Triple therapy aims to control hard-to-treat bone marrow cancer
NCT ID NCT02530463
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 23 times
Summary
This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with a chemotherapy drug (azacitidine) can help people with myelodysplastic syndromes (MDS), a bone marrow disorder. About 99 adults with MDS, including those who have not responded to prior treatments, are taking part. The goal is to see if the combination improves response rates, such as reducing cancer cells or improving blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.